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Higher prevalence of obstructive airway disease in
patients with thoracic or abdominal aortic
aneurysm
Fumio Sakamaki, MD, Hideo Oya, MD, Noritoshi Nagaya, MD, Shingo Kyotani, MD, Toru Satoh, MD,
and Norifumi Nakanishi, MD, Osaka, Japan
Background and aim: The risk factors of aortic aneurysm (AA) are comparable with those described for chronic
obstructive pulmonary disease. This study was performed to determine whether patients with AA have a higher than
average prevalence of obstructive airway disease.
Methods: We performed pulmonary function tests in 240 consecutive patients (182 men and 58 women; age, 70  10
years) with thoracic or abdominal AA. The results were compared with those in individuals without obvious cardiovas-
cular disease (control) and in patients with coronary artery disease who were matched for age, gender, smoking status, and
other atherosclerotic risk factors.
Results: Patients in the AA group had a lower forced expiratory volume in 1 second/forced vital capacity (%) and carbon
monoxide diffusing capacity (%/predicted value) than did the control group (P < .01). The proportion of patients with
airway obstruction, defined as forced expiratory volume in 1 second/forced vital capacity of 70% or less, was higher in the
AA group (100/240; 42%) than in the control (51/223; 23%) and coronary artery disease (43/238; 18%) groups.
Multiple logistic regression analysis results revealed that the presence of an AA and male gender were associated with a
higher risk of airway obstruction (odds ratio, 2.928; 95% CI, 1.722 to 4.979; and odds ratio, 1.622; 95% CI, 1.055 to
2.493, respectively).
Conclusion: These data suggest that AA may be a risk factor indicative of the presence of chronic obstructive pulmonary
disease. A higher prevalence of depressed pulmonary function should be suspected as a preoperative risk in presence of
thoracic or abdominal AA as compared with other types of cardiovascular disorders. (J Vasc Surg 2002;36:35-40.)
The quality of pulmonary function is inversely related
to the incidence of cardiac disease, including coronary
artery disease (CAD) and congestive heart failure.1,2 The
association between reduced pulmonary function and risk
of heart disease is thought to reflect similar characteristics,
such as poor physical fitness, obesity, unfavorable lipid
profiles, and tobacco abuse.3
The risk factors associated with thoracic or abdominal
aneurysms, and other cardiovascular disease, are compara-
ble with those associated with chronic obstructive pulmo-
nary disease (COPD), including age and cigarette smoking,
and the frequent presence of pulmonary emphysema com-
plicating aortic aneurysmal disease has been noted.4,5 A
high prevalence of aortic dissection or abdominal aortic
aneurysm (AAA) and an accelerated rate of aneurysm ex-
pansion have been observed in a few studies of patients with
severe COPD.6,7 In one large recent study, a weak though
significant association was found between AAA and COPD
among patients whose aneurysm was 4 cm or more in
diameter.8 Controversy, however, persists with regard to
the actual prevalence of obstructive airway disease, includ-
ing COPD, in patients with AAA, particularly among Asian
populations.
The results of pulmonary function tests performed in
240 patients with thoracic or abdominal aneurysm were
compared with those of control individuals and of patients
with CAD matched with respect to age, gender distribu-
tion, and daily cigarette consumption. The objective of this
study was to determine whether Japanese patients with
aortic aneurysms (AAs) in either the abdomen or the thorax
have a significantly higher prevalence of obstructive airway
disease than patients with other cardiovascular disorders.
STUDY POPULATIONS AND METHODS
Patients with aortic aneurysms. The index popula-
tion consisted of 240 consecutive Japanese patients with
AA referred to the pulmonary function testing laboratory of
the National Cardiovascular Center, Osaka, Japan, from
February 1997 to September 1999 (AA group). The diag-
nosis of AA was established with the presence of a more
than 40 mm-diameter aorta on contrast-enhanced com-
puted tomography of the chest or abdomen.9,10 Computed
tomographic films were interpreted by two physicians ex-
perts in vascular medicine or surgery. The AA group con-
sisted of 118 patients with AAA, 100 with thoracic AA
(TAA), and 22 with both AAA and TAA. A history of CAD,
in absence of recent symptoms or electrocardiographic
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changes as the result of myocardial ischemia within 1 year
before the study, was present in 51 patients with AA.
Exclusion criteria included dissecting AA, saccular aneu-
rysm, aneurysm as the result of aortoarteritis syndrome or
Marfan syndrome, unstable angina, unstable heart failure,
history of bronchial asthma, current wheezing, tobacco
smoking within 3 months before pulmonary function test-
ing, and the use of theophylline, -adrenergic agonists,
anticholinergic agents, and oral or inhaled corticosteroids.
Control population. Two additional age-matched
groups of patients were studied. The first was a control
group consisting of 223 consecutive Japanese patients
without apparent cardiovascular disorders. The control
group comprised 223 consecutive Japanese individuals
without apparent cardiovascular disorders referred to our
laboratory by an attending physician from our ambulatory
care department or hospital for screening cardiopulmonary
function tests. This group included 166 patients with hy-
pertension, 19 patients with diabetes, and 67 patients with
hyperlipidemia.
Coronary artery disease population. The CAD
group consisted of 238 Japanese patients, including 105
patients with stable exercise-induced angina pectoris and
133 patients with old myocardial infarctions, in absence of
recent symptoms or of electrocardiographic changes as the
result of myocardial ischemia within 1 month of pulmonary
function testing. The CAD group was studied as the second
control group. To create a group age-matched with the AA
group, consecutive patients 45 years of age or older were
selected from the control and the CAD groups because all
patients in the AA group were between the ages of 45 and
87 years. The overall number of referred patients, the
number of excluded patients for each of the major exclu-
sion criteria, and the number of patients ultimately enrolled
in this study are shown in Table I.
A detailed history of cigarette consumption and of prior
illnesses was obtained from all study participants, and blood
samples were collected for measurements of fasting serum
cholesterol. Hypertension was defined as a history of systolic
blood pressure more than 160 mm Hg and diastolic pres-
sure more than 100 mm Hg before treatment, according to
the guideline of the Joint National Committee VI.11
Hypercholesterolemia was defined as a serum cholesterol
level more than 240 mg/dL and low density lipocholes-
terol more than 130 mg/dL before treatment, according to
the guideline of National Cholesterol Education Program/
Adult Treatment Panel III.12 All study participants were
explained the purpose of the study and granted informed
consent. Important baseline clinical characteristics of the
three study populations are shown in Table II.
Pulmonary function testing. Diagnostic spirometry,
including carbon monoxide diffusing capacity (DLCO)
with single-breath technique, was performed in all study
participants with standardized equipment (FUDAC-70;
Fukuda-denshi, Tokyo, Japan) in our pulmonary function
laboratory.13 All measurements were performed in tripli-
cate before the prescription of a bronchodilator to allow a
choice of the best of three sets of data. Obstructive airway
disease was defined as a measured forced expiratory volume
in 1 second/forced vital capacity (FEV1.0/FVC) 100 of
70% or less. Other indices of pulmonary function, including
vital capacity (VC), VC/predicted value (%VC), FEV1.0,
FEV1.0/predicted value (%), forced expiratory flow rate at
50% of the VC, and DLCO also were compared among the
three groups.14
Statistical analysis. The study participant characteris-
tics, including gender, age, smoking history, level of ciga-
rette consumption (in pack-years), body height and weight,
systemic blood pressure, blood glucose and cholesterol
levels, and pulmonary function testing measurements were
systematically recorded and analyzed with computer soft-
ware for statistical analysis (Stat View 5.0; Abacus Con-
cepts, Inc, Berkeley, Calif). The association between ob-
structive airway disease, defined as FEV1/FVC of 70% or
less, and hypertension or hypercholesterolemia among the
three groups was examined with multiple comparisons rank
sum test.15
Measurements of age, cigarette consumption (pack-
years), and results of pulmonary function tests are pre-
sented as mean  standard deviation. Differences among
Table I. Numbers of patients referred, excluded for major criteria, and ultimately enrolled in each study group
Control CAD AA
Overall numbers of referred patients 287 312 320
Numbers of excluded patients 64 74 80
Dissecting aneurysm 0 0 16
Secondary aneurysm* 0 0 4
Unstable angina 0 5 2
Unstable heart failure 0 4 1
History of asthma 12 17 18
Current wheezing 8 8 9
Smoking within 3 months 34 28 21
Use of bronchodilators† 7 9 8
Steroid use‡ 3 3 1
Numbers of enrolled patients 223 238 240
*As a result of aortoaortic syndrome or Marfan syndrome.
†Theophylline, -stimulating or anticholinergic agents.
‡Oral predonisolone or inhaled beclomethasone dipropionate.
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the three groups were tested with one-way analysis of
variance with multiple comparisons. Differences were con-
sidered significant when P was less than .05 with Scheffe´
test.
Correlations between age, body height, or body weight
and pulmonary function expressed as FEV1/FVC were
tested with multiple regression analysis in each group.
Multiple logistic regression analysis was performed to as-
certain whether the presence of an AA was independently
associated with obstructive airway disease, compared with
gender, history of cigarette smoking, presence of hyperten-
sion, or CAD.
RESULTS
Important characteristics, including age, gender ratio,
body height and weight, cigarette smoking profile, and
prevalence of hypertension, did not differ among the con-
trol, CAD, and AA groups (Table II). Hypercholesterol-
emia was significantly more prevalent in the CAD group
than in the control and AA groups (P  .01).
The main results of the pulmonary function tests in the
three study groups are presented in Table III. The indices
of airway obstruction, FEV1.0/FVC ratio (%), and forced
expiratory flow rate at 50% of the VC were significantly
lower in the AA group than in the control and CAD groups
(P  .01). Furthermore, DLCO and the DLCO-alveolar
ventilatory volume ratio were significantly lower in the AA
group than in the control and CAD groups (P  .05). No
significant difference was seen in VC, VC/predicted value
(%VC), FEV1.0, and FEV1.0/predicted value (%) among
the three groups. In all three groups, FEV1.0/FVC ratio
(%) of current smokers was lower than in former or never
smokers.
The percentages of patients with obstructive airway
disease (FEV1/FVC 70%) in each group is shown in the
Fig. With multiple comparison rank sum test, patients with
AA had a significantly higher prevalence rate of airway
obstruction (100/240; 42%) than control subjects (51/
223; 23%) and patients with CAD (43/238; 18%). Further-
more, patients with AA had a higher prevalence rate of
more severe airflow obstruction, defined as a FEV1/FVC of
less than 55% (AA group: 27/240; 11.3%; control group:
20/223; 9.0%; CAD group: 11/238; 5.0%). No significant
correlation was found between size of the aneurysm and
Table II. Baseline characteristics of three study groups
Control CAD AA
No. of patients (male/Female) 223 (162/61) 238 (195/43) 240 (182/58)
Age, years; range 68.8  9.2 (47-87) 68.5  6.5 (48-89) 69.9  9.3 (45-87)
Body height (cm*) 161  8 161  7 162  9
Body weight (kg*) 60.3  10.9 60.3  10.6 58.9  10.3
Cigarette smoking history
Current smokers 87 (39%) 104 (44%) 91 (38%)
Former smokers 71 (32%) 83 (35%) 76 (32%)
Never smokers 65 (29%) 51 (21%) 73 (30%)
No. of pack-years* 48.5  33.0 52.5  43.7 49.2  35.3
Presence of hypertension 159 (71%) 146 (61%) 155 (65%)
Presence of hypercholesterolemia 56 (%) 83 (%)† 68 (%)
History of CAD 0 238 (100%) 51 (21%)
*Mean  SD. †P  .01 versus control and AA.
Current smokers patients who had smoked within 5 years and quit smoking for 3 months before pulmonary function testing; former smokers were patients
who had quit smoking for more than 5 years.
Table III. Results of pulmonary function tests in three study groups
Control CAD AA
Vital capacity (L) 2.9  2.7 3.3  5.8 3.0  4.1
FEV1.0 (L) 2.0  0.6 2.1  0.6 1.9  0.6
FEV1.0 % predicted 88.0  23.6 89.2  20.7 84.6  24.0
FEV1.0/FVC ratio (%) 74.1  12.7 75.6  10.3 70.9  12.3*
Never smokers 78.1  8.1 78.9  7.8 72.1  10.8
Former smokers 73.3  14.0# 75.9  10.4 71.9  11.2
Current smokers 70.4  13.6## 73.9  10.8# 68.4  14.8#
FEF50% /% predicted 52.4  26.9 58.5  30.0 44.9  25.1*
DLCO (mL/min/Torr) 16.8  5.1 16.6  5.2 15.1  5.1*
DLCO/% predicted 106  23 100  27* 95  24*
DLCO/VA (% predicted) 92  30 86  28 82  27*
FEV1.0 in men (in women*)  3.44 (2.67*)  body height (m)  0.033 (0.027*) age (year)  1.00 (0.54*).
Predicted values: FEF50% in men (in women*)  (0.00024 [0.00017*]  [age]2  0.0577 [0.0487*]  age  4.438 [4.086*])  body height.
DLCO in men (in women*)  (10.9 [7.1*]  body height  0.067 [0.054*]  age  5.89 [0.89*])  2.97 (2.99*).
Values are means  SD; *P  .05 versus control group; # P  .05 versus never smokers; ## P  .05 versus former smokers.
FEF50%, Forced expiratory flow at 50% of forced vital capacity; VA, alveolar ventilatory volume.
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FEV1/FVC (%) or any other measurement of pulmonary
function.
Multiple logistic regression analysis results revealed
that presence of an AA and male gender were indepen-
dently related to obstructive airway disease, in contrast to
presence of hypertension and hypercholesterolemia (Table
IV). In multiple regression analysis, FEV1/FVC correlated
negatively with patient age in the overall study population,
in the control group, and in the CAD group, and no
correlation was found between FEV1/FVC and other clin-
ical variables in the AA group. Correlation coefficients and
P values in each group are shown in Table V.
DISCUSSION
This study confirmed that Japanese patients with TAA
or AAA have a high prevalence rate of obstructive airway
disease and that pulmonary function indices of airway ob-
struction in patients with AA are lower than in a control
population and in patients with CAD. Patients with AA not
only were more likely to have an FEV1/FVC of less than
70%, as shown in the Fig, but also to have a higher preva-
lence rate of FEV1/FVC of less than 55%, which is consis-
tent with unequivocal airway obstruction. We also showed
that DLCO and DLCO-alveolar ventilatory volume ratio
were lower in patients with AA than in the control and
CAD groups. With respect to DLCO, the association be-
tween AAs and airway obstructive disease is likely the result
of an association with pulmonary emphysema rather than
with chronic bronchitis, in which DLCO is known to be
preserved.
Several clinical studies have described associations be-
tween AA and aging, male gender, cigarette smoking, and
hypertension.7,16 Except for hypertension, these factors
have often also been found to be associated with COPD.
Indeed, several studies have reported a univariate associa-
tion between AAA and COPD.17,18 Other studies have
observed comparable abnormalities in elastase activity in
both AA and COPD.19 This study supports such findings in
Asian or Japanese populations. Because our study only
addressed issues of disease prevalence, common factors that
Pie graphs show higher proportion of airway obstructive disease, defined as FEV1.0/FVC(%) 70 or less, in AA group
(100/240; 42%) than in control (51/223; 23%) or CAD (43/238; 18%) groups. Histograms show distribution of
FEV1/FVC(%) in each group.
Table IV. Results of multiple logistic regression analysis
Variable RR estimate 95% CI P value
Male gender 1.622 1.055-2.493 .0276
Presence of hypertension 0.967 0.562-1.664 .9023
Presence of hypercholesterolemia 0.634 0.369-1.090 .0993
History of CAD 1.159 0.800-1.680 .4341
Presence of AA 2.928 1.722-4.979 .0001
RR  risk ratio.
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may exist between AA and COPD could not be identified.
One may, however, hypothesize that the high prevalence of
obstructive airway disease in patients with AA is related to
common inflammatory mechanisms or that it may be the
result of a genetic susceptibility to common risk factors,
such as aging and cigarette smoking, different from other
cardiovascular disorders.20-22
On the other hand, one large study from Denmark
found no statistically significant association between AAA
and COPD after adjustment for smoking history.23 Fur-
thermore, in a recent report from the large Aneurysm
Detection and Management cohort study, COPD was not
independently associated with 3.0 cm-diameter to 3.9 cm-
diameter AAAs (odds ratio, 1.06; 95% CI, 0.97 to 1.17). In
the group with AAAs 4.0 cm or more in diameter, although
the odds ratio was significant, its value was low (1.21; 95%
CI, 1.06 to 1.38), and this association was lost after adjust-
ment for the number of years of smoking.8 From these
results, a history of cigarette smoking seems to be a pre-
dominant factor in the association between AA and COPD.
In consideration of the association of these two conditions,
smoking behavior appears to be the common denominator
underlying the susceptibility to both AA and COPD. In-
deed, the FEV1.0/FVC ratio (%) of current smokers was
lower than that of never smokers, including in the AA
group (Table II).
Several explanations may exist for the differences be-
tween our results and those of other large cohort studies,
which may be interpreted as limitations of our study. First,
because our population was Japanese, whether our results
can be extrapolated to other ethnic groups is not known.
Second, a diagnosis of airway obstruction, instead of
COPD, was used in our study because pulmonary function
tests were performed only once. However, patients with
histories of bronchial asthma, current wheezing, or use of
theophylline or -adrenergic agonists were excluded to
avoid the inclusion of patients who had reversible bronchial
constriction or who were in a phase of acute exacerbation.
Third, this study was performed at a single center, where a
high percentage of referred patients are at high surgical risk.
Therefore, our study population may have had more seri-
ous preoperative disorders, including more advanced pul-
monary disease, than at average medical institutions. In
addition, the number of patients studied may have been
relatively small compared with previous studies,8,23 and the
absence of a correlation between presence of airway ob-
struction and cigarette smoking may have been the result of
a statistical type 2 error.
In this study, a higher prevalence rate of depressed
pulmonary function was found among patients with AA
than among patients with CAD matched for multiple clin-
ical characteristics, although hypercholesterolemia was
more prevalent in the CAD group than in the AA group.
Several reports have indicated that pulmonary emphysema
also is associated with AA and is a preoperative risk factor. A
prospective study of respiratory failure after surgery for
TAA and AAA revealed that COPD was an independent
predictor of severe postoperative complications, along with
smoking history and cardiac and renal disease.24 Smith and
coworkers25 reported that appropriate preoperative care,
with a detailed respiratory assessment and careful attention
to pulmonary function in the postoperative period, was
associated with a favorable postoperative course and no
operative mortality. To our knowledge, however, a higher
prevalence rate of depressed pulmonary function in patients
with AA, compared with other atherosclerotic disorders,
had not been clearly shown, although one study found that
patients with severe COPD and a FEV1.0/VC decreased to
less than 55% had a significantly higher prevalence rate of
aortic dilatation or AAA compared with patients with less
severe COPD.6 Our data point to the importance of testing
pulmonary function and assessing the results in detail be-
fore undertaking surgical treatment of AA as compared
with other cardiovascular disease, including CAD.
In summary, patients with TAA or AAA had a high
prevalence rate of airway obstruction on pulmonary func-
tion testing, and the presence of an AA was related to the
presence of obstructive airway disease, expressed as a lower
FEV1/FVC (%) than in control subjects or patients with
CAD, who were matched for age, gender, smoking history,
and cardiovascular risk factors. One may hypothesize that
smoking is the common underlying cause of aneurysms and
obstructive airway disease in biologically susceptible pa-
tients. Further studies are needed to identify common
inflammatory or genetic mechanisms that may coexist in
obstructive airway disease and in aneurysmal vascular dis-
ease.
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Overall population correlation coefficient 0.222 0.137 0.048 0.072
P value .0001 .0131 .3838 .1403
Control group correlation coefficient 0.23 0.043 0.029 0.155
P value .0157* .6604 .7626 .0962
CAD group correlation coefficient 0.3 0.155 0.125 0.09
P value .0003 .0718 0.1518 .2397
AA group correlation coefficient 0.092 0.218 0.025 0.024
P value .3788 .0524 .8156 .8006
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